Evaluasi Efektivitas Biaya Penggunaan Terapi Kombinasi Obat Antidiabetes-Antihipertensi Pada Pasien Diabetes Mellitus Tipe 2 Dengan Hipertensi Di RSUP Sanglah

Infectious diseases have been shifted by degenerative metabolic diseases. Metabolic disease whose prevalence tends to increase is type 2 diabetes mellitus characterized by decreased insulin secretion due to insulin retention which interferes with pancreatic beta cell function, which if not handled properly will result in chronic complications. The most common complication of diabetes is hypertension, which is around 54.2%. Patients with diabetes mellitus and hypertension must take life-long therapy. This will have an impact on patient costs. In addition, the use of drug therapy for diabetes mellitus can be given with several different combinations, so the costs and outcomes of the therapy produced also vary. The varied use of drug therapy results in differences in the costs and outcomes of the therapy. Based on the results of research that has been done, the calculation of Average Cost Effectiveness Ratio (ACER) and Incremental Cost Effectiveness Ratio (ICER) shows that the most cost-effective therapeutic option is the use of antidiabetic therapy combinations of insulin sensitivity enhancers with long-acting insulin and antihypertensive groups CCB (Calcium Channel Blocker). Therefore, it can be concluded that the combination therapy of antidiabetic and antihypertensive with the most cost effectiveness based on ACER and ICER values ??is a combination of antidiabetic drug groups that increase insulin sensitivity and long-acting insulin with antihypertensive CCB.